CSF1 and neoplasm: Currently, there is a gap in knowledge regarding the impact of combining inhibitors of the CSF1/CSF1R signaling axis with cancer vaccines and whether this approach could enhance the anti-tumor responses in the tumor microenvironment of solid tumors.